Promoting Vigilance in Older People: Comparative Pharmaco-EEG and Psychometric Studies with Nicergoline by Oral and Intramuscular Administration

  • B. Saletu
  • J. Grünberger

Abstract

Earlier clinical-pharmacological investigations with nicergoline — an ergot-alkaloid with a haemodynamic action which activates metabolic processes and inhibits platelet aggregation — showed that in ageing subjects this preparation brought about significant changes in cerebral activity by comparison with placebo after both acute and chronic administration [22, 23, 4]. On computer-assisted spectral-analyses of electroencephalograms (EEG) these were seen as a reduction in slow delta- and theta-activities and an increase in alpha- and alpha- related beta-activities, and are of interest in that they seem to be precisely the opposite of age-induced EEG-changes. Various investigators [10–12, 21, 25, 32] have described increases in slow activities and decreases in alpha- and alpha-related beta-activities with advancing age. These EEG-features characteristic of old age are seen even more distinctly in organic brain syndromes of varying aetiology [20, 21, 25, 2], and represent deficits in the systems which regulate vigilance. The term “vigilance” is used to describe the dynamic state of the total neural activity which determines the availability and degree of organisation of our adaptive behaviour. Since the EEG is a direct expression of the neuronal mass activity and its patterns reflect the order of its dynamic states [23], according to Kanowski [8], the demonstration of EEG-changes should be required for all geriatric preparations which claim to influence cerebral metabolism in any way.

Keywords

Placebo Dementia Glycoside Xanthine Ouabain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arrigo A, Moglia A, Borsotti L, Massarini M, Alfonsi E, Battaglia A, Sacchetti G (1982) A double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia. Int J Clin Pharm Res 11: 33–41Google Scholar
  2. 2.
    Bente D (1964) Vigilanz, dissoziative Vigilanzverschiebung und Insuffizienz des Vigilitätsto-nus. In: Kranz H, Heinrich K (Hrsg) Begleitwirkungen und Mißerfolge der psychiatrischen Pharmakotherapie. Thieme, Stuttgart, S 13–28Google Scholar
  3. 3.
    Bente D (1977) Vigilanz: Psychophysiologische Aspekte. Verh Dtsch Ges Inn Med 83: 945–952PubMedGoogle Scholar
  4. 4.
    Bente D, Glatthaar G, Ulrich G, Lewinsky M (1979) Quantitative EEG-Untersuchungen zur vigilanzfördernden Wirkung von Nicergolin. Ergebnisse einer Doppelblindstudie bei geron- topsychiatrischen Patienten. Arzneimittel-Forsch 29: 1804–1808Google Scholar
  5. 5.
    Geßner B, Bauer W, Thomalske G, Stapf M (1979) Wirkungsnachweis von Nicergolin bei geriatrischen Personen mittels biometrischer und quantitativer EEG-Untersuchungen. Be-richt, Battelle-Institut, FrankfurtGoogle Scholar
  6. 6.
    Grünberger J (1977) Psychodiagnostik des Alkoholkranken. Ein methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Maudrich, WienGoogle Scholar
  7. 7.
    Heiss WD, Zeiler K (1978) Medikamentöse Beeinflussung der Hiradurchblutung. Pharma-kotherapie 1: 137–144Google Scholar
  8. 8.
    Kanowski F (1979) Methodenkritische Überlegungen zur Prüfung von Geriatrica. In: Kewitz H (Hrsg) Medizinisch und wirtschaftlich rationale Arzneimitteltherapie. Springer, Berlin, S 253–260Google Scholar
  9. 9.
    Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978) Langzeittherapie al-tersbedingter Insuffizienzerscheinungen des Gehirns. Dt med Wochenschr 103: 456–462CrossRefGoogle Scholar
  10. 10.
    Matejcek M, Devos JE (1976) Selected methods of quantitative EEG analysis and their ap-plication in psychotropic drug research. In: Kellaway P, Peterson I (Hrsg) Quantitative an-alytic studies in epilepsy. Raven Press, New York, S 183–205Google Scholar
  11. 11.
    Matousek M, Volavka J, Roubicek J, Roth Z (1967) EEG frequency and analysis related to age in normal adults. Electroenceph Clin Neurophysiol 23: 162–167PubMedCrossRefGoogle Scholar
  12. 12.
    Obrist WD (1979) Electroencephalographic changes in normal aging and dementia. In: Hoffmeister F, Müller C (Hrsg) Brain function in old age. Springer, Berlin New York, S 102–111Google Scholar
  13. 13.
    Saletu B (1981) Application of quantitative EEG in measuring encephalotropic and pharma-codynamic properties of antihypoxidotic/nootropie drugs. In: Scientific International Re-search (Hrsg) Drugs and Methods in C.V.D. Pergamon Press, France, S 79–115Google Scholar
  14. 14.
    Saletu B (1981) Nootropic drugs and human brain function. In: Wheatley D (Hrsg) Stress and the heart. Raven Press, New York, S 327–359Google Scholar
  15. 15.
    Saletu B, Anderer P (1980) Double-blind placebo-controlles quantitative pharmaco-EEG in-vestigations after tinofedrine i.v. in geriatric patients. Curr Ther Res 28: 1–15Google Scholar
  16. 16.
    Saletu B, Grünberger J (1978) Assessment of psychoactivity and pharmacodynamics of a cerebral vasodilating hexobendine-combination by quantitative electroencephalographic and psychometric analyses. Prog Neuro-Psychopharmacol 2: 543–551CrossRefGoogle Scholar
  17. 17.
    Saletu B, Grünberger J (1980) Antihypoxidotic and nootropic drugs: Proof of their encepha- lotropic and pharmacodynamic properties by quantitative EEG investigations. Prog Neuro- Psychopharmacol 4: 469–489CrossRefGoogle Scholar
  18. 18.
    Saletu B, Grünberger J (1982) Zur Pharmakodynamik von Vicamin: Pharmako-EEG und psychometrische Studien bei Alternden. In: Lechner H (Hrsg) Fortschritte in Pathophysio-logic, Diagnostik und Therapie cerebraler Gefäßkrankheiten. Exerpta Medica, Amsterdam, S 154–177Google Scholar
  19. 19.
    Saletu B, Grünberger J (1983) Cerebral hypoxic hypoxidosis: Neurophysiological, psycho-metric and pharmacotherapeutic aspects. Adv Biol Psychiat, vol 13. Karger, Basel, S 146–164Google Scholar
  20. 20.
    Saletu B, Grünberger J (1984) Experimentally-induced hypoxic hypoxidosis in human geronto-psychopharmacology: Pharmaco-EEG and psychometric studies. Clinical Neuro-pharmacology 7: 124–125Google Scholar
  21. 21.
    Saletu B, Grünberger J (1985) Memory dystunction and vigilance — neurophysiological and psychopharmacological aspects. Ann. N.Y. Acad. Sei., 444: 406–427CrossRefGoogle Scholar
  22. 22.
    Saletu B, Grünberger J, Linzmayer L (1979) Bestimmung der encephalotropen, psychotro- pen, und pharmakodynamischen Eigenschaften von Nicergolin mittels quantitativer Phar-mako-elektroenzephalographie und psychometrischer Analysen. Arzneimittel-Forsch 29: 1251–1261Google Scholar
  23. 23.
    Saletu B, Grünberger J, Linzmayer L, Anderer P (1979) Proof of CNS efficacy and pharma-codynamics of nicergoline in the elderly by acute and psychometric studies. In: Tognoni G, Garattini S (Hrsg) Drug treatment in chronic cerebrovascular disorders. Biomedical Press. Elsevier/North-Holland, Amsterdam, S 245–272Google Scholar
  24. 24.
    Saletu B, Griinberger J, Linzmayer L (1980) Quantitative EEG and psychometric analyses in assessing CNS-activity of RO13-5057 — a cerebral insufficiency improver. Method Find Exp Clin Pharmacol 2: 269–285Google Scholar
  25. 25.
    Saletu B, Griinberger J, Linzmayer L, Pietschmann H (1982) Neurophysiological aspects of aging, dementia and its pharmacotherapy. In: Ohashi H, Nakayama K, Saito M, Saletu B (Hrsg) WPA Regional Symposium Kyoto. The Japanese Society of Psychiatry and Neurology, Tokyo, S 272–281Google Scholar
  26. 26.
    Saletu B, Griinberger L, Linzmayer L, Stöhr H (1982) Objective measures in determining the central effectiveness of a new anti-hypoxidotic SL 76188: Pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly. Arch Geronto Geriatr 1: 261–285Google Scholar
  27. 27.
    Saletu B, Saletu M, Griinberger J, Mader R (1983) Spontaneous and drug-induced remission of alcoholic organic brain syndrome. Psychiatry Research 10: 59–75PubMedCrossRefGoogle Scholar
  28. 28.
    Saletu B, Griinberger J, Linzmayer L, StÖhr H (1984) Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: Double blind, placebo-controlled pharmaco-EEG and psychometric studies. Int J Clin Pharm Res I V: 95–107Google Scholar
  29. 29.
    Saletu B, Griinberger J, Linzmayer L, Wittek R (1984) Classification and determination of pharmacodynamics of a new antihypoxidotic drug, vinconate, by pharmaco-EEG and psy-chometry. Arch Gerontol Geriatr 3: 127–146PubMedCrossRefGoogle Scholar
  30. 30.
    Saletu B, Griinberger J, Linzmayer L, Stöhr H (1984) Zur Funktionsverbesserung des alternden Gehirns: Placebo-kontrollierte Pharmako-EEG und psychometrische Studien mit einem stoffwechselaktiven Hämoderivat (Actovegin®). Z. Gerontol. 17: 271–279PubMedGoogle Scholar
  31. 31.
    Strughold H (1944) Hypoxydose. Klin Wochenschr 23: 221–222CrossRefGoogle Scholar
  32. 32.
    Surwillo W (1968) Timing of behavior in senescence and the role of the central nervous system. In: Talland E (Hrsg) Human Aging and Behavior. Academic Press, New York, S 1–33Google Scholar
  33. 33.
    Zerssen V.D, Koeller DM, Rey ER (1970) Die Befindlichkeitsskala ( B-S) — ein einfaches Instrument zur Objektivierung von Befindlichkeitsstörungen, insbesondere im Rahmen von Längsschnittuntersuchungen. Arzneimittel-Forsch 20: 915–918Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • B. Saletu
  • J. Grünberger
    • 1
  1. 1.Department of Psychiatry, School of MedicineUniversity of ViennaViennaAustria

Personalised recommendations